In a recent announcement, Pfizer Inc. confirmed that its Meningococcal Group B Vaccine, TRUMENBA® has been approved by the FDA and is now available to U.S. health professionals for active vaccination.
TRUMENBA®, which deters Neisseria mengingitidis serogroup B from taking viral control, is the only vaccine of its type to be approved by the FDA.
“We have been working around the clock since TRUMENBA was approved by the U.S. Food and Drug Administration on Oct. 29 to supply TRUMENBA in the U.S., as the most frequent question we have been asked following approval is when the vaccine would be available here,” Susan Silbermann, president and general manager of Pfizer Vaccines, said. “As of Nov. 18, TRUMENBA is available for order by healthcare providers, retail pharmacies, hospitals and college health centers who may be interested in stocking and administering the vaccine. We continue to work very closely with the CDC’s Advisory Committee on Immunization Practices to help inform discussions and potential recommendations regarding prevention of meningococcal group B disease through vaccination, an important step to improve access to TRUMENBA and help in the prevention of such a devastating disease.”
Individuals with the virus experience rapid onsets of the disease within just 24 hours.
Patients ages 11 to 24 years old make up 30 percent of the serogroup B diagnoses in the United States. The death rates for this group is recorded at 10 percent.
If adolescent patients (ages 15 to 19) survive the sickness, 60 percent of them experience permanent impairment in the form of hearing loss, neurological damage, or amputation.
The FDA approved the vaccine for all citizens from age 10 to 25.
Health professionals can order TRUMENBA directly from Pfizer. The company has stock available for retail pharmacies, hospitals, physician’s offices, college health centers and other medical practices.